1. Home
  2. MERC vs BYSI Comparison

MERC vs BYSI Comparison

Compare MERC & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

HOLD

Current Price

$0.90

Market Cap

56.9M

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

N/A

Current Price

$1.57

Market Cap

58.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MERC
BYSI
Founded
1968
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.9M
58.4M
IPO Year
2005
2016

Fundamental Metrics

Financial Performance
Metric
MERC
BYSI
Price
$0.90
$1.57
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$2.25
N/A
AVG Volume (30 Days)
489.8K
22.4K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
7.01%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,169,145,000.00
N/A
Revenue This Year
$13.75
N/A
Revenue Next Year
$10.12
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.50
N/A
52 Week Low
$0.75
$1.18
52 Week High
$4.47
$3.44

Technical Indicators

Market Signals
Indicator
MERC
BYSI
Relative Strength Index (RSI) 44.93 51.80
Support Level $0.75 $1.56
Resistance Level $1.20 $1.83
Average True Range (ATR) 0.08 0.13
MACD 0.01 0.00
Stochastic Oscillator 41.49 61.76

Price Performance

Historical Comparison
MERC
BYSI

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: